Ionis Pharmaceuticals, headquartered in Carlsbad, California, develops drugs using antisense technology and has five marketed medicines, including SPINRAZA and QALSODY, with a pipeline focused on neurology and cardiology. The company employs 927 people and has nine medicines in Phase III development.
IONS has been in the news recently: Ionis Pharmaceuticals Inc. (IONS) closed at $42.81 and experienced a premarket increase to $43.83 following insider trading news, while the FDA approved its drug IONS Dawnzera for preventing hereditary angioedema attacks in patients aged 12 and older. Additionally, Tharimmune Inc. saw a rise in its shares after positive simulation results for its lead asset, TH104.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
